Alligator Bioscience AB appoints Sibylle Lenz as Chief Executive Officer

18-Jun-2010 - Sweden

Alligator Bioscience AB announced that it has appointed Sibylle Lenz, Pharm. Dr, as its new Chief Executive Officer (CEO). Mrs Lenz, who joins Alligator Bioscience from Dako A/S and who previously has had a long successful career at H. Lundbeck A/S, has significant senior management experience in the pharmaceutical industry and has been appointed to lead the Company as it embarks on a new phase of international clinical and commercial development. Mrs Lenz will take up her position on 1st August 2010.

Sibylle Lenz is an experienced pharmaceutical executive who has held senior positions in the diagnostics and pharmaceutical industry. She joins Alligator Bioscience from Dako A/S, a cancer diagnostics company where she was Vice President, Corporate Business Development.

From 2001 to 2008 Mrs Lenz held a number of senior international commercial positions in H. Lundbeck A/S and prior to that Mrs Lenz gained more than ten years of experience in different research and development positions, also in H. Lundbeck A/S. Mrs Lenz holds a PhD specialized in medicinal chemistry from the Danish University of Pharmaceutical Sciences.

Other news from the department people

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures